Clinical trial NCT04935580: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
Official title: Frontline Therapy of GC012F Injection in Transplant Eligible Newly Diagnosed Multiple Myeloma Patients With High-Risk Profile
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Multiple Myeloma
Lead sponsor: Shanghai Changzheng Hospital
Sponsor class: OTHER
Collaborators: name: Gracell Biotechnologies (Shanghai) Co., Ltd.
First posted: 2021-06-23
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplant eligible patients with NDMM.

Detailed description: Twenty evaluable subjects are planned to be enrolled in this study. Apheresis will be carried out in subjects who meet eligible criteria, and total 2 cycles of induction therapy (three-drug combination regimen based on bortezomib with details determined by the investigator according to the patient's condition) will be selectively given to subjects before or after apheresis. Next, subjects will receive a single infusion of GC012F, and the efficacy assessments will be performed at 1 month, 3 months, and every 3 months within 2 years until the end of the trial (MRD testing is required for each efficacy assessment),

1.Efficacy assessments performed at the 1st and 3rd months after infusion:

1. \<PR: Protocol change or transplantation or follow-up decided by the investigator.
2. ≥PR: MRD positive: Protocol change or transplantation or follow-up decided by the investigator.

MRD negative: Wait for next follow-up.

2.Efficacy assessments performed at the 6th month after infusion and every 3 months thereafter:

1. MRD positive: Protocol change or transplantation or follow-up decided by the investigator.
2. MRD negative: Whether to carry out maintenance treatment using lenalidomide until the end of the trial will be determined by the investigator.

After signing the informed consent form (ICF), subjects will be followed up for efficacy and safety until 2 years after GC012F infusion, or disease progression, or death, or withdrawal of consent, or any intolerable toxicity, whichever comes first. All AEs in subjects, especially infection related symptoms and signs, will be closely monitored during follow-up, and prophylactic treatment will be administered according to clinical practice when necessary. In case of disease progression within 2 years after GC012F infusion, treatment will be administered according to clinical practice, and the survival follow-up (only for the survival status) will be performed every 12 weeks±14 days (2 weeks) until 2 years after infusion, or death, or withdrawal of consent, whichever comes first. For subjects who have undergone transportation or any other clinical routine treatments after GC012F infusion, survival follow-up will be also performed as described above.

Eligibility criteria: Inclusion Criteria:

* Patients should meet all of the following criteria:

  1. ≥18 years of age at the time of signing informed consent-upper age limit 70;
  2. High-risk defined as meet one or more of the following criteria at screen:

     1. R-ISS stage II or III;
     2. LDH \> the upper limit of normal;
     3. Meet one or more of cytogenetic high risk defined by: del 17p, t(4:14), t(14:16); Gain 1q21≥ 4 copies;
     4. Patients with extramedullary disease;
     5. IgD or IgE subtype;
     6. Meet one or more high-risk definition of mSMART3.0;
  3. Documented evidence of multiple myeloma at diagnosis as defined by IMWG guidelines CRAB (calcium elevation, renal insufficiency, anemia, and bone abnormalities)/SLiM criteria, monoclonal plasma cells in the bone marrow ≥10% or presence of a biopsy proven plasmacytomas, and measurable secretory disease according to IMWG criteria meet one or more of the following criteria at screening:

     1. Serum M protein ≥ 1 g/dL;
     2. Urine M protein ≥ 200 mg/24h;
     3. Serum free light chain sFLC ≥ 10 mg/dL with abnormal serum immunoglobulin κ/λ free light chain ratio.
  4. ECOG score was 0-2 at screen;
  5. Estimated life expectancy ≥3 months;
  6. Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L without use of growth factors;
  7. Platelet count ≥ 75×10\^9/L without transfusion support within 7 days before the screen;
  8. Hemoglobin≥ 80 g/L;
  9. Adequate functional reserve of organs:

     1. ALT/AST ≤ 2.5× UNL (upper normal limit);
     2. Creatinine clearance ≥ 40mL/min, or serum creatinine level ≤177μmol/L，may be calculated or measured according to local practice;
     3. Serum total bilirubin ≤ 1.5× UNL, except in subjects with congenital bilirubinemia, such as Gilbert syndrome, then direct bilirubin ≤ 1.5× UNL;
     4. The left ventricular ejection fraction (LVEF)≥50%, and no clinically significant ecg abnormalities were found;
     5. Basic oxygen saturation in natural indoor air: SPO2\>92%.
  10. Adequate venous access for apheresis collection, and no other contraindications to apheresis;
  11. Subjects and sexual partner with fertility are willing to use effective and reliable method of contraception for at least 1 year after CART cell infusion, serum HCG should be negative in females with fertility both at screening andbaseline;
  12. Subjects must sign a written informed consent.

Exclusion Criteria:

* Patients should be excluded if they meet any one of the following criteria:

  1. Patients with purely non-secretory MM;
  2. Subject has had radiation therapy within 14 days of screening;
  3. Subjects has plasma cell leukemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes);
  4. Subjects has a diagnosis of primary amyloidosis, Waldenstroem's disease, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma;
  5. Having other tumors (excluding non-melanoma skin cancer and cervical cancer in situ bladder cancer and breast cancer that have been disease-free for more than 5 years);
  6. Overt clinical evidence of dementia or altered mental status; any history of central nervous system (CNS) disease or neurodegenerative disorder, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain damage, dementia, Parkinson's disease, psychosis;
  7. History of hereditary diseases such as Fanconi anemia, Schrader syndrome, Costerman syndrome, or any other known bone marrow failure syndrome;
  8. Clinically significant cardiac disease including: uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities, grade III-IV heart failure or myocardial infarction cardiac angioplasty or stenting unstable angina or other clinically significant cardiac conditions within one year prior to enrollment;
  9. Presence of any indwelling catheter or drainage tube (e.g., percutaneous nephrostomy catheter indwelling catheter bile drainage tube or pleural/peritoneal/pericardial catheter) permits the use of a dedicated central venous catheter;
  10. Subjects is exhibiting clinical signs of meningeal involvement of multiple myeloma;
  11. A positive virological result for any of the following: HIV, HCV, HBsAg, TPPA;
  12. Other severe viral or bacterial infections or uncontrolled systemic fungal infections are present;
  13. Subjects with a history of severe hypersensitivity;
  14. There is a history of an autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that has resulted in terminal organ damage or requires systemic immunosuppressive/disease modulating drugs in the past 2 years;
  15. Presence of lung disease (such as pulmonary fibrosis);
  16. Subjects has had major surgery within 2 weeks before screen or has not fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study;
  17. Poor compliance due to factors such as physiological family, social geography, etc., and inability to comply with the research program and follow-up plan;
  18. Pregnant or lactating women, or men who are planned to have babies during the period of participation in the study or within 1 year of receiving treatment;
  19. Investigator assessment deemed to be ineligible.

Primary outcomes:
measure: Adverse Events (AE) after GC012F infusion
timeFrame: Up to 1 year after patients infused with GC012F injection
measure: Overall response rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Percentage of patients with minimal residual disease (MRD) negative(tested by NGF at sensitivity of 10e-5 to 10e-4) at landmark analysis of 1/3/6/12/18/24 months post GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Progress free survival (PFS) at 6 months, 12 months and 24 months after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Duration of response (DOR) at 6 months, 12 months and 24 months after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
Secondary outcomes:
measure: Overall survival (OS) after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Time to first response (TTR) after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Time to best response (TBR) after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Change from Baseline in Health-related Quality of Life (HRQoL) as Measured by EORTC QLQ-C30
timeFrame: Baseline up to study completion ( 2 years after GC012F Infusion on Day 0
measure: Change from Baseline in HRQoL as Measured by EORTC QLQ-MY20
timeFrame: Baseline up to study completion ( 2 years after GC012F Infusion on Day 0
measure: Change from Baseline in Participant-reported Health Status Measured by EQ-5D- 5L
timeFrame: Baseline up to study completion ( 2 years after GC012F Infusion on Day 0
measure: Change from Baseline in Pain Measured by PGIS Scale [Time Frame: Baseline up to study completion
timeFrame: Baseline up to study completion ( 2 years after GC012F Infusion on Day 0
measure: Level of CAR-T Cell Expansion (proliferation), and Persistence
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Cytokines in the peripheral blood after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Serum concentrations of C-reaction protein (CRP)
timeFrame: Up to 2 years after patients infused with GC012F injection
measure: Number of patients with Anti-GC012F Antibodies, replication-competent lentivirus (RCL) after GC012F infusion
timeFrame: Up to 2 years after patients infused with GC012F injection
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Changzheng Hospital
state: Shanghai
Study officials:
affiliation: Shanghai Changzheng Hospital
name: Juan Du, MD
role: PRINCIPAL_INVESTIGATOR
References: